Drug Trial Radar · NCT01104584
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
Last checked: Nov 19, 2026Latest source record: Nov 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
460
Actual
Start
May 2010
Primary completion
Sep 2011
Study completion Jan 2012
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Apr 15, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining MR images of both breasts.Women with a recent diagnosis of breast cancer by mammogram (X-ray examination of the breasts) may benefit from MRI of the breasts as MRI may detect additional breast cancers
Conditions
- Breast Cancer
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug
A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference of Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per ReaderTime frame: Immediately before injection and after injection
- Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per ReaderTime frame: Immediately before injection and after injection
- Breast Level Specificity of CMRM for Non-malignant Breasts by ReaderTime frame: Immediately before injection and after injection
Locations
48 sites in 9 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
Oakland, California
Site not named
Englewood, Colorado
Site not named
Chicago, Illinois
Site not named
New York, New York
Site not named
Columbus, Ohio
Site not named
Providence, Rhode Island
Site not named
San Antonio, Texas
Site not named
Tacoma, Washington
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Hamilton, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Berlin, Germany
Site not named
Erlangen, Bavaria, Germany
Site not named
München, Bavaria, Germany
Site not named
Frankfurt am Main, Hesse, Germany
Site not named
Göttingen, Lower Saxony, Germany
Site not named
Göttingen, Lower Saxony, Germany
Site not named
Greifswald, Mecklenburg-Vorpommern, Germany
Site not named
Bochum, North Rhine-Westphalia, Germany
Site not named
Münster, North Rhine-Westphalia, Germany
Site not named
Münster, North Rhine-Westphalia, Germany
Site not named
Gera, Thuringia, Germany
Site not named
Delhi, India
Site not named
Mumbai, India
Site not named
Mumbai, Maharashtra, India
Site not named
Maastricht, Netherlands
Site not named
Nijmegen, Netherlands
Site not named
Eindhoven, EJ, Netherlands
Site not named
Bydgoszcz, Poland
Site not named
Gliwice, Poland
Site not named
Krakow, Poland
Site not named
Szczecin, Poland
Site not named
Warsaw, Poland
Site not named
Córdoba, Spain
Site not named
Barcelona, Barcelona, Spain
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.